Horizon and Mallinckrodt to co-promote Duexis

Monday, June 18, 2012 09:54 AM

Mallinckrodt, the pharmaceuticals business of Covidien, has entered into a co-promotion agreement with Horizon Pharma of Deerfield, Ill., to promote the latter’s proprietary drug Duexis, a single-tablet combination of ibuprofen and the histamine H2-receptor antagonist famotidine for symptom relief of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers.

Mallinckrodt’s U.S. sales force will sell Duexis through December 31, 2014. Horizon and Mallinckrodt have agreed upon physician promotion targets and Mallinckrodt will be compensated for each prescription generated from these targets. The Mallinckrodt sales force is expected to begin promoting Duexis to physicians in August 2012. Horizon will continue to record all revenues and remain responsible for Duexis manufacturing, supply and regulatory activities.

"This agreement represents a key component of our growing pharmaceuticals business as Mallinckrodt prepares to spin off from Covidien next year,” said Mark Trudeau, president of pharmaceuticals, Mallinckrodt. “We are leaders in pain management, and adding Duexis to our portfolio will further advance our efforts to help patients manage the often-debilitating impact of pain.”

Mallinckrodt is the largest U.S. supplier of opioid pain medications and among the top 10 generic pharmaceuticals manufacturers in the U.S., based on prescriptions. Its branded portfolio includes Exalgo (hydromorphone HCl) extended-release tablets and Pennsaid (diclofenac sodium topical solution) 1.5% w/w. Mallinckrodt is also one of the world’s leading producers of bulk acetaminophen.

“The addition of Mallinckrodt’s experienced sales force will expand our reach and frequency into the osteoarthritis and rheumatology markets,” said Timothy P. Walbert, chairman, president and CEO, Horizon Pharma.




Browse by:


April 21

Healthcare IPOs soar in first quarter

Survey compares 'push/pull' tactics in patient recruitment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs